Ultimovacs (OSE: ULTI)

Last close As at 08/11/2024

NOK7.55

0.06 (0.80%)

Market capitalisation

260m

Edison Investment Research is terminating coverage on Ultimovacs (ULTI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Latest Insights

View More

Healthcare | Flash note

Ultimovacs — Steadfast commitment to UV1 progression

Healthcare | Flash note

Ultimovacs — UV1 hits transitory roadblock with INITIUM top-line

Healthcare | edison tv

Ultimovacs – executive interview

Ultimovacs_resized

Sector

Healthcare

Balance Sheet

Forecast net debt (NOKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 6.9 (93.9) (93.6)
Relative 5.1 (94.4) (94.3)
52 week high/low NOK160.4/NOK6.3

Financials

Edison Investment Research is terminating coverage on Oxford Cannabinoid Technologies (OCTP), Britvic (BVIC), Ultimovacs (ULTI), DFR Gold (DFR), The Merchants Trust (MRCH), PB Holding (PBH) and Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Dec Revenue (NOKm) EBITDA (NOKm) PBT (NOKm) EPS (fd) (öre) P/E (x) P/CF (x)
2022A 0.0 (181.0) (167.8) (489.9) N/A N/A
2023A 0.0 (213.0) (189.2) (550.1) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Research

Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — Line of sight on INITIUM top-line readout

Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — Two for two in melanoma Phase I trial

Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — UV1 ODD a sign of positive things to come

Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — Positive Phase I update in malignant melanoma

Update

Healthcare

Ultimovacs — UV1 by no means out after NIPU readout

Update

Healthcare

Ultimovacs — On track for upcoming UV1 catalysts

edison tv

Healthcare

Ultimovacs – executive interview

edison tv

Healthcare

Ultimovacs – executive interview

Flash note

Healthcare

Ultimovacs — Further positivity for UV1

Update

Healthcare

Ultimovacs — UV1 development funded past key readouts

Flash note

Healthcare

Ultimovacs — Patient expansion in Phase I TENDU

Flash note

Healthcare

Ultimovacs — Positive Phase I survival data in melanoma

Flash note

Healthcare

Ultimovacs — UV1 Phase II data flow creeps closer

edison tv

Healthcare

Ultimovacs – executive interview

edison tv

Healthcare

Ultimovacs – executive interview Test

Update

Healthcare

Ultimovacs — New large indication for UV1

edison tv

Healthcare

Ultimovacs – Edison Open House interview

QuickView

Healthcare

Ultimovacs — Phase II data from 500+ patients over 2022/23

QuickView

Healthcare

Ultimovacs — Cancer vaccine with near-universal potential